ROSEVILLE, Minn., February 23, 2022/PR Newswire/ — Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt” or the “Company”), a plant-based synthetic biology company, today announced the closing of its previously announced placement to an institutional investor in an underwritten offering of 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and common warrants to purchase up to 7,760,000 shares of its common stock (the “Offering”).
Canaccord Genuity acted as the sole bookrunner for the Offering.
The net proceeds to the Company from the Offering, after underwriting discounts and expenses, were approximately $10.0 million, assuming none of the accompanying common warrants issued in the Offering are exercised. The Company intends to use the net proceeds from the Offering for enhancing the capabilities of its BioFactory production system and increasing its capacity to produce at larger scales, continuing to build out its PlantSpring technology platform and artificial intelligence / machine learning capabilities, furthering customer relationships, and for working capital and general corporate purposes.
The above-referenced securities were offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-233231) previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on September 27, 2019. The Offering was made by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and accompanying prospectus relating to the Offering were filed with the SEC on February 22, 2022. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at http://www.sec.gov or by contacting Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, Suite 1200, Boston, Massachusetts 02110, or by email at prospectus@cgf.com..
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in the Offering, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Calyxt
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce innovative and high value plant-based chemistries for use in customers’ materials and products. As plant-based solutions, the Company’s synthetic biology products can be used in helping customers meet their sustainability targets and financial goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about the intended use of net proceeds from the Offering. You are cautioned not to place undue reliance on any forward-looking statements made by Calyxt’s management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Actual results could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to those discussed under the caption entitled “Risk Factors” in our Annual Report on Form 10-K and subsequent filings on Form 10-Q or 8-K with the U.S. Securities and Exchange Commission. Calyxt does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
Contacts:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen / John Garabo Argot Partners (212) 600-1902 media@calyxt.com
ROSEVILLE, Minn., February 17, 2022 /PR Newswire/ — Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt” or the “Company”), a plant-based synthetic biology company, today announced the placement to an institutional investor in an underwritten offering of 3,880,000 shares of its common stock, pre-funded warrants to purchase up to 3,880,000 shares of its common stock, and common warrants to purchase up to 7,760,000 shares of its common stock (the “Offering”). The shares of common stock and the pre-funded warrants are each being sold in combination with corresponding common warrants, with one common warrant to purchase one share of common stock for each share of common stock or each pre-funded warrant sold. The pre-funded warrants will have an exercise price of $0.0001 per share of common stock and the common warrants will have an exercise price of $1.41 per share of common stock. The pre-funded warrants will be immediately exercisable and remain exercisable until exercised, while the common warrants will be exercisable six months after the date of issuance and will have a term of five years from the date of exercisability. The aggregate public offering price for each share of common stock or each pre-funded warrant and, in each case, an accompanying common warrant is $1.41. All securities to be sold in the Offering were sold by the Company.
The Company expects to close the Offering on or about February 23, 2022, subject to the satisfaction of customary closing conditions. The gross proceeds from the Offering are expected to be approximately $10.9 million, assuming none of the accompanying common warrants issued in the Offering are exercised. The Company intends to use the net proceeds from the Offering for enhancing the capabilities of its BioFactory production system and increasing its capacity to produce at larger scales, continuing to build out its PlantSpring technology platform and artificial intelligence / machine learning capabilities, furthering customer relationships, and for working capital and general corporate purposes.
There is no established public trading market for the pre-funded warrants or the common warrants and the Company does not expect a market to develop. Additionally, the Company does not intend to apply for the listing of the pre-funded warrants or the common warrants on any national securities exchange or other nationally recognized trading system.
Canaccord Genuity is acting as the sole bookrunner for the Offering.
The Offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-233231) that was declared effective by the Securities and Exchange Commission (the “SEC”) on September 27, 2019. The Offering will be made only by means of a prospectus supplement and accompanying prospectus describing the terms of the Offering. Copies of the prospectus supplement and the accompanying prospectus relating to this Offering may be obtained, when available, by contacting Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, Suite 1200, Boston, Massachusetts 02110, or by email at prospectus@cgf.com. These documents may also be obtained for free on the SEC’s website located at http://www.sec.gov.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in the Offering. There shall not be any sale of these securities in any state or jurisdiction in which such offering, sale or solicitation would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce innovative and high value plant-based chemistries for use in customers’ materials and products. As plant-based solutions, the Company’s synthetic biology products can be used in helping customers meet their sustainability targets and financial goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the Offering and the expected uses of the proceeds from the Offering. Completion of the Offering is subject to numerous factors, many of which are beyond Calyxt’s control, including, without limitation, market conditions, failure of customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements made by Calyxt’s management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Calyxt does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
Contacts:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen/ John Garabo Argot Partners (212) 600-1902 media@calyxt.com
Roseville, MN – Monday, February 7, 2022 –Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that Gerry Nuovo has joined Calyxt as Senior Vice President of Business Development. He brings more than 30 years of experience in the specialty chemicals and biotechnology industries and diverse experience building multimillion-dollar income streams in the personal care and home care markets. Mr. Nuovo will be responsible for business development functions, including potential partnerships, deal structures, valuation models, and subsequent transaction execution and alliance management.
“We’re thrilled to welcome Gerry at this exciting time for our team,” said Michael A. Carr, President and Chief Executive Officer of Calyxt. “His experience is well aligned with our strategy to deliver plant-based synthetic biology solutions to important new customers in identified key end markets, and his track record in cosmetics, nutraceuticals and beauty is particularly timely as we continue to focus our business development efforts on these and other key markets, helping customers produce products that meet their corporate sustainability goals.”
“Calyxt is a synthetic biology company that delivers unique and innovative plant-based solutions not available through other production methods, and the integration of its proprietary PlantSpring™ technology platform with its BioFactory™ production system, enables Calyxt to rapidly prototype and produce complex plant-derived compounds,” said Mr. Nuovo. “It’s a compelling and differentiated offering for customers, and I look forward to working alongside this dynamic executive team.”
Mr. Nuovo most recently served as Vice President of Commercialization & Global Business Development at C16 Biosciences, where he led global commercialization of its novel technology platform focused on an alternative to conflict agricultural palm oil and downstream derivatives. Prior, he served as Sales Director, Americas, Personal Care at Cargill, Inc. and as Vice President, Global Market Development, Consumer Products at Rivertop Renewables. Previously, Mr. Nuovo held senior business development and sales roles at Segetis, Codexis, Inc., and Firmenich, Inc.
Mr. Nuovo holds a B.S. in Biology and Chemistry from William Paterson University of New Jersey.
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer innovative materials and products for its customers to help them meet their sustainability goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory, Plant Cell Matrix™, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about Calyxt’s product pipeline and development; Calyxt’s ability to utilize the BioFactory to engineer precursor molecules and to convert these to broader chemistries demanded by potential customers; Calyxt’s ability to achieve target molecule production and performance at greater scale; and the commercial demand for Calyxt’s synthetic biology solutions. These and other forward-looking statements are predictions and projections about future events and trends based on Calyxt’s current expectations, objectives, and intentions and are premised on current assumptions. Calyxt’s actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the impact of increased competition, including competition from a broader array of synthetic biology companies; disruptions at Calyxt’s key facilities, including disruptions impacting its BioFactory production system; changes in customer preferences and market acceptance of Calyxt’s products; competition for customers, partners, and licensees and the successful execution of development and licensing agreements; the impact of adverse events during development, including unsuccessful pilot production of compounds or generation of inconsistent data; disruptions to supply chains, including raw material inputs for Calyxt’s BioFactory; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; and other important factors discussed under the caption entitled “Risk Factors” in Calyxt’s Annual Report on Form 10-K and subsequent filings on Form 10-Q or Form 8-K with the U.S. Securities and Exchange Commission. Any forward-looking statements made by Calyxt’s management are based only on information currently available to it when, and speak only as of the date, such statement is made. Calyxt does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
Contacts:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen/ John Garabo/ Michael Barron Argot Partners (212) 600-1902 media@calyxt.com
Roseville, MN – January 6, 2022 –Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that its pilot BioFactory™ production system, installed in late December 2021, is now operational at its headquarters site in Minnesota.
“I am proud of the effort our team and suppliers made to achieve this milestone on schedule, as it marks an important step in the scaling of our production. The data we collect and analyze will drive future decisions as well as help improve our test cycles and development timeline,” said Michael A. Carr, President and Chief Executive Officer of Calyxt. “We are encouraged by the number of inbounds from potential customers regarding our technology and the quality of our conversations. We are seeking customer orders of two to four compounds for development by year end 2022, and as a result are using our selection criteria to determine the compounds to pursue based on customer need. We look forward to providing further updates on our continued scaling and customer acquisition throughout the year.”
On October 5, 2021, Calyxt announced the launch of a strategic initiative that focused the Company on engineering synthetic biology solutions for a diversified base of customers using its expanded proprietary PlantSpring™ technology platform. The output from PlantSpring is integrated with the Company’s BioFactory production system, enabling Calyxt to rapidly prototype and produce complex plant-derived compounds without the need for outdoor cropping systems.
Calyxt’s proprietary Plant Cell Matrix™ systems have been placed in the BioFactory, where they will be used for testing at pilot-scale production. The pilot is currently in its testing period, during which time the Company will ensure the system, including its data generation and communication capabilities for artificial intelligence modeling, is working as expected. This is a key step in understanding the scaling capability of the BioFactory production system.
About the PlantSpring™ Technology Platform and BioFactory™ Production System
Calyxt’s technology platform, PlantSpring, is founded on the Company’s more than a decade of experience engineering plant metabolism, and includes its scientific knowledge, its proprietary systems, tools, and technologies; and an expanding set of AIML capabilities. This licensable platform delivers innovation through an efficient development process. The process includes identification of breakthrough compounds based on customer needs, design strategies to reprogram host cells, engineering of plant cell metabolism to optimally produce targeted plant-based chemistries, and production of those target chemistries at laboratory scale. Calyxt has developed early-stage AIML capabilities in PlantSpring, which enable learning and adaptation of knowledge gained from past activity and can be combined with predictive analytics to rapidly prototype and provide feedback, accelerating the time to complete the design-engineer-verify development cycle and helping mitigate the risk associated with commercial scale-up. As a result, Calyxt believes it can develop biomolecules in plants for customers at faster speeds than its competitors in the synthetic biology industry. The output from the PlantSpring platform integrates with the Company’s newly commissioned BioFactory production system.
The BioFactory production system is the culmination of the work of Calyxt’s researchers and will enable the Company to expand its production methods from solely outdoor agriculture systems to also include controlled environment, bioreactor-based production systems. The BioFactory harnesses the potential of plant cells in a multicellular matrixed structure and utilizes nutrient media for its production. The BioFactory leverages multiple cell types, and the multicellular matrix structures enable processing of plant-based chemistries of increased complexity relative to those possible using traditional fermentation systems or single cell plant culture methods. In addition, the speed of the matrix growth over time is expected to accelerate the production of the compound at scale. As a result, Calyxt’s production system is capable of unlocking the power of plants to produce complex compounds that are finite, difficult to source sustainably, and that may not be able to be produced using other production methods. Calyxt has been running lab-scale bioreactors for several months and its first pilot-scale bioreactor has been commissioned and is expected to be online by the end of 2021. There may be a range of vessel sizes between the initial pilot facility and commercial production. For transition from pilot to commercialization, the Company’s current plan is to use third parties, referred to as infrastructure partners, for at-scale BioFactory production. Because of its production methodology, Calyxt believes the BioFactory has the potential to be one of the most sustainable production systems across industries.
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer innovative materials and products for its customers to help them meet their sustainability goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory, Plant Cell Matrix, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about Calyxt’s product pipeline and development; Calyxt’s ability to utilize the BioFactory to engineer precursor molecules and to convert these to broader chemistries demanded by potential customers; Calyxt’s ability to achieve target molecule production and performance at greater scale; and the commercial demand for Calyxt’s synthetic biology solutions. These and other forward-looking statements are predictions and projections about future events and trends based on Calyxt’s current expectations, objectives, and intentions and are premised on current assumptions. Calyxt’s actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the impact of increased competition, including competition from a broader array of synthetic biology companies; disruptions at Calyxt’s key facilities, including disruptions impacting its BioFactory production system; changes in customer preferences and market acceptance of Calyxt’s products; competition for customers, partners, and licensees and the successful execution of development and licensing agreements; the impact of adverse events during development, including unsuccessful pilot production of compounds or generation of inconsistent data; disruptions to supply chains, including raw material inputs for Calyxt’s BioFactory; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; and other important factors discussed under the caption entitled “Risk Factors” in Calyxt’s Annual Report on Form 10-K and subsequent filings on Form 10-Q or Form 8-K with the U.S. Securities and Exchange Commission. Any forward-looking statements made by Calyxt’s management are based only on information currently available to it when, and speak only as of the date, such statement is made. Calyxt does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
Contacts:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen/John Garabo/Michael Barron Argot Partners (212) 600-1902 media@calyxt.com
Roseville, MN – Tuesday, January 4, 2022 –Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that a presentation given by management at the H.C Wainwright BioConnect Conference will be available for viewing online on Monday, January 10, 2022 at 7:00 a.m. ET. The conference will be held in a virtual meeting format.
– Represents significant progress in sustainable discovery and development of plant-based molecules in Calyxt’s BioFactory
– Forms a baseline library of chemistries and building block precursors availablefor valuable downstream markets like cosmetics, nutraceuticals, and pharmaceuticals
– Pilot BioFactory remains on track to be operational by end of 2021
Roseville, MN – December 8, 2021 –Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the completion of a key milestone in its lab-scale BioFactory™ manufacturing system. The results identified through the Company’s metabolomics analyses indicate over 15,000 chemical signatures, including both known and as-yet-uncharacterized molecules and building block precursors, chemical compounds involved in chemical reactions that produce other compounds. These chemical signatures form a baseline library available for Calyxt to produce valuable compounds within its proprietary plant-based biomanufacturing system.
“With this technical milestone, Calyxt builds on our earlier proofs of concept and bolsters our commercial discussions, particularly because the families of chemistries identified in these results perform important functions as active ingredients in certain of our target markets, like cosmetics, pharmaceuticals and nutraceuticals,” said Michael A. Carr, President and Chief Executive Officer at Calyxt. “The promise of the BioFactory – to enable our customers to more sustainably access finite botanical ingredients – is one step closer to being realized through these results.”
The metabolomics analyses have identified molecules across a diverse and valuable group of chemical classes including terpenoids, flavonoids, phenolics, alkaloids, and sterols, plus chemical signatures that may represent new, previously uncharacterized plant-based molecules. In addition, Calyxt has recently completed gene-expression profiling that has identified patterns of genes that can be used to engineer precursor molecules for conversion to an even broader suite of chemistries.
“These impactful results build on our previously reported successes with two proofs of concept, ovalbumin egg white protein and the antioxidant betanin. Early research indicated our multicellular plant cell matrices would be capable of producing a diverse group of chemistries, and that is supported by the analysis announced today. This broad set of building blocks provide important tools as we seek to engineer the new and innovative chemistries our customers are expected to demand,” said Travis Frey, Ph.D., Chief Technology Officer at Calyxt. “From here, guided by customers’ needs and our proprietary metabolite engineering capabilities, we anticipate the optimization of target molecule production and performance at greater scale.”
Calyxt’s BioFactory will produce the target products, first at lab volumes, then at pilot, and ultimately at manufacturing scale. The Company’s pilot BioFactory is currently being installed at its Roseville, Minnesota, headquarters and is on track to be operational by the end of 2021.
PlantSpring, BioFactory, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about Calyxt’s product pipeline and development; Calyxt’s ability to utilize the BioFactory to engineer precursor molecules and to convert these to broader chemistries demanded by potential customers; Calyxt’s ability to achieve target molecule production and performance at greater scale; and the commercial demand for Calyxt’s synthetic biology solutions. These and other forward-looking statements are predictions and projections about future events and trends based on Calyxt’s current expectations, objectives, and intentions and are premised on current assumptions. Calyxt’s actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the impact of increased competition, including competition from a broader array of synthetic biology companies; disruptions at Calyxt’s key facilities, including disruptions impacting its BioFactory production system; changes in customer preferences and market acceptance of Calyxt’s products; competition for customers, partners, and licensees and the successful execution of development and licensing agreements; the impact of adverse events during development, including unsuccessful pilot production of compounds or generation of inconsistent data; disruptions to supply chains, including raw material inputs for Calyxt’s BioFactory; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; and other important factors discussed under the caption entitled “Risk Factors” in Calyxt’s Annual Report on Form 10-K and subsequent filings on Form 10-Q or Form 8-K with the U.S. Securities and Exchange Commission. Any forward-looking statements made by Calyxt’s management are based only on information currently available to it when, and speak only as of the date, such statement is made. Calyxt does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
Contacts:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen/John Garabo/Michael Barron Argot Partners (212) 600-1902 media@calyxt.com
Roseville, MN – December 6, 2021 –Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the hiring of two senior roles important to furthering Calyxt’s recently announced strategic direction. Joining the Company are Vijay Gullapalli, Ph.D., as Vice President, Artificial Intelligence/Machine Learning (AI/ML) and Data Science, reporting to Travis Frey, Ph.D., Chief Technology Officer; and Pete Ball as Technology Licensing Leader, reporting to Debra Frimerman, General Counsel and Corporate Secretary.
“I welcome Vijay and Pete to Calyxt as key hires to help drive our strategy to deliver plant-based synthetic biology solutions to important customers in our identified key end markets. We aim to enable these customers to create target products from formerly finite ingredients while delivering against their corporate sustainability goals,” said Michael A. Carr, President and Chief Executive Officer at Calyxt.
“At Calyxt, we are using our PlantSpring™ technology platform to create bespoke molecules from plants, for a variety of end markets. PlantSpring relies on an iterative prototyping cycle of design, engineer, verify and learn, aided by AI and machine learning capabilities. Vijay’s experience and expertise building innovative AI-based solutions will be invaluable as we continue to develop and augment those AI and machine learning capabilities within PlantSpring,” added Mr. Carr. “Further, Pete’s addition to the team will enable us to advance our licensing activities in both our platform technologies, including IP relating to gene-editing in plants, and our portfolio of crop innovations. We welcome Pete’s deep legal acumen and proven ability to build value through partnering.”
Dr. Gullapalli brings nearly 25 years of experience in developing solutions for businesses across diverse industries utilizing his expertise in data technology and AI/machine learning. He joins Calyxt from Blue Cross Blue Shield of North Carolina, where he served as Vice President of Analytics & Insights. Previously, he worked at Capital One, serving as Director, Card Machine Learning and Data Transformation and HSBC, as Vice President, Global Information Management. Prior to these roles, Dr. Gullapalli served as Chief Technology Officer at Hypertech Solutions. He holds a B.S. in Electrical Engineering, an M.S. in Mathematics from Birla Institute of Technology & Science, Pilani, India, and an M.S. and Ph.D. in Computer Science, Machine Learning, from the University of Massachusetts, Amherst.
Mr. Ball has nearly 35 years of legal and technology licensing experience and joins Calyxt from North Shore Therapeutics, where he served as Chief Executive Officer. Prior to North Shore, he served as Chief Corporate Development Officer at ConsenSys Health. Previously, Mr. Ball served as Senior Technology Licensing Manager at Mayo Clinic Ventures, and as Portfolio Director, Technology Licensing at Johns Hopkins Technology Ventures. In addition to his experience in software development, Mr. Ball has a background in operations management, having begun his career at United Parcel Service. Mr. Ball holds a B.A. in Psychobiology from Hamilton College, an M.S. in Operations Research from Columbia University, and a J.D. from the University of Baltimore, School of Law.
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer innovative materials and products for its customers to help them meet their sustainability goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Contacts:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen/John Garabo/Michael Barron Argot Partners (212) 600-1902 media@calyxt.com
Roseville, MN – Tuesday, November 23, 2021 –Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced that management will present at the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum.
2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer innovative materials and products for its customers to help them meet their sustainability goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com
Contact:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen Argot Partners (212) 600-1902 media@calyxt.com
-Announced new strategic direction to provide sustainably produced plant-based synthetic biology solutions to expanded group of end markets and diversified base of customers, leveraging its proprietary PlantSpring™ Technology Platform and BioFactory™ Production System-
-Commissioned first pilot BioFactory, expected to be online by the end of 2021-
-Appointed IBM’s Global Chief Artificial Intelligence Officer, Dr. Seth Dobrin, to Calyxt’s Scientific Advisory Board (SAB)-
-Launched a $50.0 million at-the-market (ATM) share issuance program-
-Entered into a research collaboration with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a sustainable commercial alternative to palm oil-
-Sold nearly all the 2020 grain crop to Archer Daniels Midland (ADM), generating $35.7 million in total cash since sales commenced in Q3 2020-
-Net cash used by operating activities improved by $16.2 million year-over-year-
-Management to host conference call and webcast today at 4:30 p.m. ET-
Roseville, MN – November 4, 2021 –Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biotechnology company, today announced financial results for its third quarter ended September 30, 2021.
“Since I joined the Company as CEO in July, Calyxt has made significant progress, aligning on a new strategic direction that leverages our Company’s strengths and key areas of differentiation, and positions Calyxt as a synthetic biology company in its own right,” said Michael A Carr, President and Chief Executive Officer at Calyxt. “The cornerstone of our strategy is to leverage our proprietary PlantSpring technology platform with our BioFactory production system, which together enable us to provide plant-based synthetic biology solutions to important end markets and target customers, and thus help these customers produce products that meet their corporate sustainability goals. These target customers provide an enormous opportunity for Calyxt, and include companies within such industries as nutraceuticals, cosmeceuticals, personal care, advanced materials and chemicals.”
Mr. Carr added: “We recently welcomed Dr. Seth Dobrin, IBM’s Global Chief Artificial Intelligence Officer, to our Scientific Advisory Board. Seth’s deep experience bringing AI-based business solutions to major global corporations will be valuable as we continue to develop and augment our artificial intelligence and machine learning capabilities. We believe we can develop engineered biomolecules in plants for customers at faster speeds than our competitors in the synthetic biology industry. With Seth’s guidance, we aim to achieve further efficiency in our processes. Concurrently, we continue to license our technology and develop products for agricultural customers based on their needs, including our recently announced research collaboration with a leading global food ingredient manufacturer, which marked an important validation of our technology platform and for Calyxt’s evolution to a partner-driven innovation model. I look forward to driving continued progress across our business to realize value for our shareholders.”
Key accomplishments in the third quarter of 2021 and through the date of this release include:
In October, the Company announced the launch of a strategic initiative that will focus Calyxt on engineering synthetic biology solutions for a diversified base of customers across an expanded group of end markets, including the nutraceutical, cosmeceutical, pharmaceutical, advanced materials, and chemicals industries. Central to the strategy is the integration of the Company’s proprietary technology platform, PlantSpring, with its BioFactory production system, which together will enable Calyxt to rapidly prototype and produce complex plant-derived compounds without the need for outdoor cropping systems. The Company estimates that, aided by artificial intelligence and machine learning (AIML), it will be able to take a customer’s plant-based chemistry need through Calyxt’s development cycle and pilot-level production process within a 36-month period, with commercial scale production to commence thereafter. The final output, based upon the engineering of plant metabolism to efficiently produce plant-based compounds, is designed to provide customers across industries a safe and more sustainable supply of these compounds for use in a myriad of products and manufacturing processes.
The Company has commissioned its first pilot BioFactory production system and it is expected to be online by the end of 2021.
In October 2021, the Company announced the appointment of Seth Dobrin, Ph.D., to its SAB. Dr. Dobrin is the Global Chief Artificial Intelligence (AI) Officer at IBM and brings extensive leadership experience and a track record of transforming companies through data and AI. Dr. Dobrin’s deep experience bringing AI-based business solutions to major global corporations will be valuable as the Company continues to develop and augment the AIML capabilities of its PlantSpring platform and BioFactory production system.
Entered into a research collaboration with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a sustainable commercial alternative to palm oil. As part of the research collaboration, the Company will receive cash payments in each of the two years of its term. This collaboration agreement also includes a commercial option for the global food ingredient manufacturer.
Completed the sale of nearly all the 2020 grain crop to ADM, with the remaining grain projected to be sold by the end of the calendar year. This series of transactions, which began in the third quarter of 2020, has generated $35.7 million in total cash since sales commenced.
Net cash used by operating activities improved by $16.2 million from the same period a year ago driven primarily by an improvement in the Company’s working capital investment and operating expenses associated with the wind-down of its soybean product line.
Financial Results for the Three Months Ended September 30, 2021
Revenue was $7.8 million in the third quarter of 2021, an increase of $2.5 million, or 48 percent, from the third quarter of 2020. The increase was driven by the volume and mix of product sold in the quarter, as the Company sold grain in the third quarter of 2021 as compared to the third quarter of 2020, when the Company was primarily selling soybean oil and meal. As of September 30, 2021, the Company had sold substantially all of the 2020 grain crop.
Cost of goods sold was $8.3 million in the third quarter of 2021, an increase of $1.2 million, or 17 percent, from the third quarter of 2020. The increase was driven by higher volumes of product sold and higher average prices paid for grain due to increases in commodity market prices for soybeans. These increases were partially offset by the benefits resulting from the move to sell grain compared to selling primarily soybean oil and meal, as well as a $2.1 million year-over-year benefit from unrealized commodity derivative gains from hedging contracts entered into to convert fixed price grain inventories and forward purchase contracts to floating prices, consistent with how the grain was sold. As a result of the continued wind-down of the Company’s soybean product line, it held no commodity derivative contracts at September 30, 2021.
Gross profit was negative $0.5 million, or negative seven percent of revenue, in the third quarter of 2021, compared to negative $1.8 million, or negative 35 percent of revenue, in the third quarter of 2020. This increase of $1.3 million, or 71 percent, from the third quarter of 2020 was largely driven by the benefits resulting from the move to sell grain compared to selling primarily oil and meal, as well as a $2.1 million year-over-year benefit from unrealized commodity derivative gains, as described above.
See below under the heading “Use of Non-GAAP Financial Information” for a discussion of adjusted gross profit and adjusted gross profit percentage and a reconciliation of gross profit and gross profit percentage, the most comparable GAAP measure, to adjusted gross profit and adjusted gross profit percentage, respectively.
Total operating expenses were $6.4 million in the third quarter of 2021, a decrease of $0.8 million, or 11 percent, from $7.2 million in the third quarter of 2020. The decrease was driven by lower personnel expenses as a result of cost reductions following the move to sell grain compared to selling oil and meal, other reductions in operating expenses, and restructuring costs recognized in the third quarter of 2020.
Net loss was $7.3 million in the third quarter of 2021, an improvement of $2.2 million, or 23 percent, from the third quarter of 2020. The improvement in net loss was driven by improved gross profits and reduced operating expenses. Net loss per share was $0.20 in the third quarter of 2021, an improvement of $0.09 per share, or 31 percent, from the third quarter of 2020. The improvement in net loss per share was driven by the change in net loss and the year-over-year increase in the weighted average share count.
Adjusted net loss was $9.1 million in the third quarter of 2021, essentially flat compared to the third quarter of 2020. Adjusted net loss per share was $0.24 in the third quarter of 2021, an improvement of $0.04 per share, or 14 percent, from the third quarter of 2020. The improvement in adjusted net loss per share was driven by the year-over-year increase in the weighted average share count.
See below under the heading “Use of Non-GAAP Financial Information” for a discussion of adjusted net loss and adjusted net loss per share, and reconciliations of net loss and net loss per share, the most comparable GAAP measures, to adjusted net loss and adjusted net loss per share.
Adjusted EBITDA loss was $6.9 million in the third quarter of 2021, essentially flat compared to the third quarter of 2020.
See below under the heading “Use of Non-GAAP Financial Information” for a discussion of adjusted EBITDA and a reconciliation of net loss, the most comparable GAAP measure, to adjusted EBITDA.
Net cash used by operating activities was $3.4 million in the third quarter of 2021, an improvement of $1.8 million from the third quarter of 2020. This cash performance was driven by collections from the sale of grain to ADM, continued declines in the working capital investment associated with the wind down of that grain sales activity, and strong operating expense management.
Cash, cash equivalents, and restricted cash totaled $14.9 million as of September 30, 2021.
“Over the past nine months, we realized a $16.2 million year-over-year improvement in cash flow from operations as a result of increased product sales, improved gross profits, a reduction in our working capital investment associated with our soybean product line, and strong management of cash expenditures. We have raised $3.7 million since putting our ATM facility in place and are on track to achieve our target for cash operating expenses for the year of $25 million or lower, an amount that at this time is also inclusive of any BioFactory-related spending in the fourth quarter,” said Bill Koschak, Calyxt’s Chief Financial Officer.
Third Quarter 2021 Results Conference Call
Calyxt’s President and Chief Executive Officer Michael A. Carr and Chief Financial Officer Bill Koschak will host a conference call discussing Calyxt’s results for the third quarter of 2021, followed by a question-and-answer session where they will be joined by Dr. Travis Frey, the Company’s Chief Technology Officer. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of Calyxt’s website at www.calyxt.com.
To access the call, please use the following information:
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will also be broadcast live and available for replay via the investor relations section of the company’s website at www.calyxt.com.
A replay of the webcast will be available for 30 days following the event.
Toll Free Replay Number:
+1-877-344-7529
International Replay Number:
+1-412-317-0088
Replay ID:
10161186
About the PlantSpring™ Technology Platform and BioFactory™ Production System
Calyxt’s technology platform, PlantSpring, is founded on the Company’s more than a decade of experience engineering plant metabolism, and includes its scientific knowledge, its proprietary systems, tools, and technologies; and an expanding set of AIML capabilities. This licensable platform delivers innovation through an efficient development process. The process includes identification of breakthrough compounds based on customer needs, design strategies to reprogram host cells, engineering of plant cell metabolism to optimally produce targeted plant-based chemistries, and production of those target chemistries at laboratory scale. Calyxt has developed early-stage AIML capabilities in PlantSpring, which enable learning and adaptation of knowledge gained from past activity and can be combined with predictive analytics to rapidly prototype and provide feedback, accelerating the time to complete the design-engineer-verify development cycle and helping mitigate the risk associated with commercial scale-up. As a result, Calyxt believes it can develop biomolecules in plants for customers at faster speeds than its competitors in the synthetic biology industry. The output from the PlantSpring platform integrates with the Company’s newly commissioned BioFactory production system.
The BioFactory production system is the culmination of the work of Calyxt’s researchers and will enable the Company to expand its production methods from solely outdoor agriculture systems to also include controlled environment, bioreactor-based production systems. The BioFactory harnesses the potential of plant cells in a multicellular matrixed structure and utilizes nutrient media for its production. The BioFactory leverages multiple cell types, and the multicellular matrix structures enable processing of plant-based chemistries of increased complexity relative to those possible using traditional fermentation systems or single cell plant culture methods. In addition, the speed of the matrix growth over time is expected to accelerate the production of the compound at scale. As a result, Calyxt’s production system is capable of unlocking the power of plants to produce complex compounds that are finite, difficult to source sustainably, and that may not be able to be produced using other production methods. Calyxt has been running lab-scale bioreactors for several months and its first pilot-scale bioreactor has been commissioned and is expected to be online by the end of 2021. There may be a range of vessel sizes between the initial pilot facility and commercial production. For transition from pilot to commercialization, the Company’s current plan is to use third parties, referred to as infrastructure partners, for at-scale BioFactory production. Because of its production methodology, Calyxt believes the BioFactory has the potential to be one of the most sustainable production systems across industries.
About Calyxt:
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer innovative materials and products for its customers to help them meet their sustainability goals. Calyxt’s diversified offerings are primarily delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory, and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Contacts:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen/Sarah Sutton/John Garabo Argot Partners (212) 600-1902 media@calyxt.com
Sarah Reiter Calyxt, Inc. (612) 427-7881 contact@calyxt.com
USE OF NON-GAAP FINANCIAL INFORMATION
To supplement the Company’s financial results prepared in accordance with GAAP, it has prepared certain non-GAAP measures that include or exclude special items. These non-GAAP measures are not meant to be considered in isolation or as a substitute for financial information presented in accordance with GAAP and should be viewed as supplemental and in addition to financial information presented in accordance with GAAP. Investors are cautioned that there are material limitations associated with the use of non-GAAP financial measures. In addition, other companies may report similarly titled measures, but calculate them differently, which reduces their usefulness as a comparative measure. Management utilizes these non-GAAP metrics as performance measures in evaluating and making operational decisions regarding Calyxt’s business.
The Company’s non-GAAP financial measures reflect adjustments for certain commodity derivatives entered into in connection with its soybean product line. As a result of the continued wind-down of this product line, the Company held no commodity derivative contracts at September 30, 2021.
The Company presents adjusted gross profit and adjusted gross profit percentage, which are non-GAAP measures. Adjusted gross profit reflects adjustments necessary to present the underlying gross profit of its soybean product line, including (i) unrealized gains and losses associated with commodity derivatives entered into to hedge the change in value of fixed price grain inventories and fixed price forward purchase contracts that should be recognized in the future when the underlying inventory is sold, (ii) gains and losses from commodity derivatives realized in prior periods but associated with inventory sold in the current period, (iii) net realizable value adjustments to inventories occurring in the period which otherwise would have been recognized in the future when the underlying inventory is sold, and (iv) net realizable value adjustments recognized in prior periods but associated with inventory sold in the current period. Adjusted gross profit percentage is derived from adjusted gross profit, a non-GAAP measure, and total revenue.
The Company provides in the table below a reconciliation of gross profit and gross profit percentage, which are the most directly comparable GAAP financial measures, to adjusted gross profit and adjusted gross profit percentage. The Company provides adjusted gross profit and adjusted gross profit percentage because it believes that these non-GAAP financial metrics provide investors with useful supplemental information as the amounts being adjusted affect the period-to-period comparability of gross profit and financial performance.
The table below presents a reconciliation of gross profit and gross profit percentage to adjusted gross profit and adjusted gross profit percentage:
The Company presents adjusted net loss, a non-GAAP measure, and defines it as net loss including adjustments necessary to present the underlying gross profit of its soybean product line, including (i) unrealized gains and losses associated with commodity derivatives entered into to hedge the change in value of fixed price grain inventories and fixed price forward purchase contracts that should be recognized in the future when the underlying inventory is sold, (ii) gains and losses from commodity derivatives realized in prior periods but associated with inventory sold in the current period, (iii) net realizable value adjustments to inventories occurring in the period which otherwise would have been recognized in the future when the underlying inventory is sold, and (iv) net realizable value adjustments recognized in prior periods but associated with inventory sold in the current period, and excluding cash-based Section 16 officer transition expenses, restructuring costs, the recapture of non-cash stock compensation associated with the departure of Section 16 officers and restructuring-related staffing adjustments made in the third quarter of 2020, the gain upon the extinguishment of the Payroll Protection Plan (PPP) loan, and non-operating expenses, which are primarily gains and losses on foreign exchange transactions and losses on the disposals of land, buildings, and equipment.
The Company provides in the table below a reconciliation of net loss, which is the most directly comparable GAAP financial measure, to adjusted net loss. The Company provides adjusted net loss because it believes that this non-GAAP financial metric provides investors with useful supplemental information at this stage of commercialization as the amounts being adjusted affect the period-to-period comparability of net losses and financial performance.
The table below presents a reconciliation of net loss to adjusted net loss:
The Company presents adjusted net loss per share, a non-GAAP measure, and defines it as net loss per share including adjustments necessary to present the underlying gross profit of its soybean product line, including (i) unrealized gains and losses associated with commodity derivatives entered into to hedge the change in value of fixed price grain inventories and fixed price forward purchase contracts that should be recognized in the future when the underlying inventory is sold, (ii) gains and losses from commodity derivatives realized in prior periods but associated with inventory sold in the current period, (iii) net realizable value adjustments to inventories occurring in the period which otherwise would have been recognized in the future when the underlying inventory is sold, and (iv) net realizable value adjustments recognized in prior periods but associated with inventory sold in the current period, and excluding cash-based Section 16 officer transition expenses, restructuring costs, the recapture of non-cash stock compensation associated with the departure of Section 16 officers and restructuring-related staffing adjustments made in the third quarter of 2020, the gain upon the extinguishment of the PPP loan, and non-operating expenses, which are primarily gains and losses on foreign exchange transactions and losses on the disposals of land, buildings, and equipment.
The Company provides in the table below a reconciliation of net loss per share, which is the most directly comparable GAAP financial measure, to adjusted net loss per share. The Company provides adjusted net loss per share because it believes that this non-GAAP financial metric provides investors with useful supplemental information at this stage of commercialization as the amounts being adjusted affect the period-to-period comparability of net losses per share and financial performance.
The table below presents a reconciliation of net loss per share to adjusted net loss per share:
The Company presents adjusted EBITDA, a non-GAAP measure, and defines it as net loss including adjustments necessary to present the underlying gross profit of its soybean product line, including (i) unrealized gains and losses associated with commodity derivatives entered into to hedge the change in value of fixed price grain inventories and fixed price forward purchase contracts that should be recognized in the future when the underlying inventory is sold, (ii) gains and losses from commodity derivatives realized in prior periods but associated with inventory sold in the current period, (iii) net realizable value adjustments to inventories occurring in the period which otherwise would have been recognized in the future when the underlying inventory is sold, and (iv) net realizable value adjustments recognized in prior periods but associated with inventory sold in the current period, and excluding interest, net, depreciation and amortization expenses, non-cash stock compensation expenses including the recapture of non-cash stock compensation associated with the departure of Section 16 officers and restructuring-related staffing adjustments made in the third quarter of 2020, cash-based Section 16 officer transition expenses, restructuring costs, the gain upon the extinguishment of the PPP loan, and non-operating expenses, which are primarily gains and losses on foreign exchange transactions and losses on the disposals of land, buildings, and equipment.
The Company provides in the table below a reconciliation of net loss, which is the most directly comparable GAAP financial measure, to adjusted EBITDA. Because adjusted EBITDA excludes non-cash items and discrete or infrequently occurring items, the Company believes that adjusted EBITDA provides investors with useful supplemental information about the operational performance of its business and facilitates the period-to-period comparability of financial results where certain items may vary significantly independent of business performance.
The table below presents a reconciliation of net loss to adjusted EBITDA:
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include statements about our future financial performance, including the Company’s cash runway; its product pipeline and development; its business model and strategies for the development, commercialization, and sales of commercial products; commercial demand for its synthetic biology solutions; the development and deployment of its PlantSpring technology platform; its ability to deploy and leverage AI and ML capabilities; the ability to scale production capability for its BioFactory production system; potential development agreements, partnerships, customer relationships, and licensing arrangements and their contribution to its financial results, cash usage, and growth strategies; and anticipated trends in its business. These and other forward-looking statements are predictions and projections about future events and trends based on the Company’s current expectations, objectives, and intentions and are premised on current assumptions. The Company’s actual results, level of activity, performance, or achievements could be materially different than those expressed, implied, or anticipated by forward-looking statements due to a variety of factors, including, but not limited to: the severity and duration of the evolving COVID-19 pandemic and the resulting impact on macro-economic conditions; the impact of increased competition, including competition from a broader array of synthetic biology companies; disruptions at the Company’s key facilities, including disruptions impacting its BioFactory production system; flaws in AI and ML algorithms, insufficiency of data inputs required by such algorithms, and human error in interacting with AI and ML; changes in customer preferences and market acceptance of its products; changes in market consensus as to what attributes are required for a product to be considered “sustainable”; competition for customers, partners, and licensees and the successful execution of development and licensing agreements; the impact of adverse events during development, including unsuccessful pilot production of compounds or field trials; the impact of improper handling of its product candidates during development; failures by third-party contractors; inaccurate demand forecasting or milestone and royalty payment projections; the effectiveness of commercialization efforts by commercial partners or licensees; disruptions to supply chains, including raw material inputs for our BioFactory; the impact of changes or increases in oversight and regulation; disputes or challenges regarding intellectual property; proliferation and continuous evolution of new technologies; management changes; dislocations in the capital markets; and other important factors discussed under the caption entitled “Risk Factors” in the Company’s Annual Report on Form 10-K and subsequent filings on Form 10-Q or Form 8-K with the U.S. Securities and Exchange Commission. Any forward-looking statements made by management of the Company are based only on information currently available to it when, and speak only as of the date, such statement is made. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
CALYXT, INC.
CONSOLIDATED BALANCE SHEETS
(In Thousands, Except Par Value and Share Amounts)
CALYXT, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited and in Thousands Except Shares and Per Share Amounts)
Roseville, MN – Tuesday, October 19, 2021 –Calyxt, Inc. (Nasdaq: CLXT) will hold a conference call on Thursday, November 4, 2021, at 4:30 p.m. Eastern time to discuss its results for the third quarter ended on September 30, 2021. A press release detailing these results will be issued prior to the call.
Chief Executive Officer Michael A. Carr and Chief Financial Officer Bill Koschak will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here.
To access the call, please use the following information:
Date:
Thursday, November 4, 2021
Time:
4:30 p.m. EST, 1:30 p.m. PST
Toll Free dial-in number:
+1 888-317-6003
Toll/International dial-in number:
+1 412-317-6061
Conference ID:
1329064
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. The conference call will also be broadcast live and available for replay via the investor relations section of the Company’s website here. A replay of the webcast will be available for 30 days following the event.
A replay of the call will be available for one month following the conference.
Toll Free Replay Number:
+1 877-344-7529
International Replay Number:
+1 412-317-0088
Replay ID:
10161186
About Calyxt
Calyxt (Nasdaq: CLXT) is a plant-based synthetic biotechnology company. The Company leverages its proprietary PlantSpring™ technology platform to engineer innovative materials and products for its customers to help them meet their sustainability goals. Calyxt’s diversified offerings are delivered through its proprietary BioFactory™ production system. For more information, visit www.calyxt.com.
PlantSpring, BioFactory and the Calyxt logo are trademarks of Calyxt, Inc. Any other trademarks belong to their respective owners.
Contacts:
Calyxt Media Contact:
Calyxt Investor Relations Contact:
David Rosen/Sarah Sutton/John Garabo Argot Partners (212) 600-1902 media@calyxt.com
Sarah Reiter Calyxt, Inc. (612) 427-7881 contact@calyxt.com
Hello!
Hello!
Hello!
Hello!
Collaboration Inquiries
Contact Us
Search
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they as essential for the working of basic functionalities of the website.
We also use third-party cookies that help us analyze and understand how you use this website, to store user preferences and provide them with content and advertisements that are relevant to you. These cookies will only be stored on your browser with your consent to do so. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Cookie
Duration
Description
cookielawinfo-checkbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Cookie
Duration
Description
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
Targeting/Advertisement cookies are used to deliver visitors with customized advertisements based on the pages they visited before and analyze the effectiveness of the ad campaign.
Cookie
Duration
Description
cookielawinfo-checkbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.